David A. Siegel Albireo Pharma, Inc. Transaction History

Two Sigma Advisers, LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$18.01 - $23.78 $16,209 - $21,402	-900 Reduced 7.56%	11,000 $237,000
Q3 2022 Nov 14, 2022	SELL	$16.32 - $26.37 $230,112 - $371,817	-14,100 Reduced 54.23%	11,900 $230,000
Q2 2022 Aug 15, 2022	SELL	$18.54 - $37.29 $337,428 - $678,678	-18,200 Reduced 41.18%	26,000 $516,000
Q1 2022 May 16, 2022	SELL	$23.94 - $33.74 $45,486 - $64,106	-1,900 Reduced 4.12%	44,200 $1.32 Million
Q4 2021 Feb 14, 2022	SELL	$21.19 - $31.29 $525,512 - $775,992	-24,800 Reduced 34.98%	46,100 $1.07 Million
Q3 2021 Nov 15, 2021	SELL	$27.36 - $35.98 $2.26 Million - $2.98 Million	-82,700 Reduced 53.84%	70,900 $2.21 Million
Q2 2021 Aug 16, 2021	SELL	$28.9 - $36.87 $1.68 Million - $2.15 Million	-58,300 Reduced 27.51%	153,600 $5.4 Million
Q1 2021 May 17, 2021	BUY	$32.03 - $42.85 $326,706 - $437,070	10,200 Added 5.06%	211,900 $7.47 Million
Q4 2020 Feb 16, 2021	BUY	$31.56 - $42.16 $5.14 Million - $6.87 Million	163,000 Added 421.19%	201,700 $7.57 Million
Q3 2020 Nov 16, 2020	BUY	$23.19 - $41.61 $396,549 - $711,531	17,100 Added 79.17%	38,700 $1.29 Million
Q2 2020 Aug 14, 2020	BUY	$14.82 - $29.92 $68,172 - $137,632	4,600 Added 27.06%	21,600 $572,000
Q1 2020 May 15, 2020	BUY	$11.67 - $27.23 $78,189 - $182,441	6,700 Added 65.05%	17,000 $278,000
Q4 2019 Feb 14, 2020	BUY	$16.92 - $28.96 $174,276 - $298,288	10,300 New	10,300 $262,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.